Please login to the form below

Not currently logged in

European pharma patent court deal sealed

New London-based court will begin work from 2015

European Unified Patent Court signing
EU Member State ministers at the signing ceremony for the international agreement on a Unified Patent Court (Picture: The Council of the European Union)

The agreement to set up a new European patent court specialising in pharma and life science cases has been finalised, putting it on course to be up and running from 2015.

Based in London, the court will create a single destination for companies looking to defend their intellectual property, rather than forcing them to fight their case in each European country as at present.

In doing so it should prevent contradictory court rulings on the same issues and, according to the UK government, offer industry a “significant” reduction in the costs associated with patent litigation.

Business secretary Vince Cable said: “The decision that London should host this new court shows not only the confidence in our legal sector but also the strength of the UK's intellectual property regime. 

“The agreement will help our inventors who can in future spend more time on research and development, producing new ideas and less time filling in forms and defending their patents in court.”

The CEO of the UK's BioIndustry Association Steve Bates said: “It is great that the Central Division of the Unified Patent Court that covers the pharmaceutical and life sciences industries is to be based in London. This will enhance the UK's pre-eminent position in the provision of legal expertise for European life science intellectual property. 

"This, alongside the fact that Britain is a great place to start a biotech business, means that London not only hosts the Central Division patent court for life sciences but also the European regulator for medicines and devices - the European Medicines Agency at Canary Wharf - and makes the UK the natural European home for global life science companies.”

The agreement settles the details of the overarching Unified Patent Court, which will have a second specialist court in Munich focusing on mechanical engineering and a Paris-based central court.

The agreement is part of a package of measures that will provide a one-stop shop for innovative enterprises to register and protect their patents in the European Union. According to European Commission (EC), it is estimated the plan could save businesses using the patent system in Europe between €150-290m each year. 

The Unified Patent Court is the third and final element of the EC's 'patent package' and follows regulations establishing a single patent package and its associated language regime, the arrangements for which were adopted in December last year.

The final stage will be for the agreements to be ratified by Member States' national parliaments, with at least 13 of the EU's 27 members states required to do so if it is to pass into law.

20th February 2013

From: Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...